Cross-Talk between Alternatively Spliced UGT1A Isoforms and Colon Cancer Cell Metabolism.

Mol Pharmacol

Pharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center and Faculty of Pharmacy (Y.A.-D., Mi.R., Me.R., J.R., C.G.), Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec (S.M., F.P.), and Centre Hospitalier Universitaire de Québec Research Center and Faculty of Medicine (B.T.), Laval University, Québec, Canada

Published: March 2017

Alternative splicing at the human glucuronosyltransferase 1 gene locus (UGT1) produces alternate isoforms UGT1A_i2s that control glucuronidation activity through protein-protein interactions. Here, we hypothesized that UGT1A_i2s function as a complex protein network connecting other metabolic pathways with an influence on cancer cell metabolism. This is based on a pathway enrichment analysis of proteomic data that identified several high-confidence candidate interaction proteins of UGT1A_i2 proteins in human tissues-namely, the rate-limiting enzyme of glycolysis pyruvate kinase (PKM), which plays a critical role in cancer cell metabolism and tumor growth. The partnership of UGT1A_i2 and PKM2 was confirmed by coimmunoprecipitation in the HT115 colon cancer cells and was supported by a partial colocalization of these two proteins. In support of a functional role for this partnership, depletion of UGT1A_i2 proteins in HT115 cells enforced the Warburg effect, with a higher glycolytic rate at the expense of mitochondrial respiration, and led to lactate accumulation. Untargeted metabolomics further revealed a significantly altered cellular content of 58 metabolites, including many intermediates derived from the glycolysis and tricarboxylic acid cycle pathways. These metabolic changes were associated with a greater migration potential. The potential relevance of our observations is supported by the down-regulation of UGT1A_i2 mRNA in colon tumors compared with normal tissues. Alternate UGT1A variants may thus be part of the expanding compendium of metabolic pathways involved in cancer biology directly contributing to the oncogenic phenotype of colon cancer cells. Findings uncover new aspects of UGT functions diverging from their transferase activity.

Download full-text PDF

Source
http://dx.doi.org/10.1124/mol.116.106161DOI Listing

Publication Analysis

Top Keywords

colon cancer
12
cancer cell
12
cell metabolism
12
metabolic pathways
8
ugt1a_i2 proteins
8
cancer cells
8
cancer
6
cross-talk alternatively
4
alternatively spliced
4
spliced ugt1a
4

Similar Publications

Knockdown of LAMA3 enhances the sensitivity of colon cancer to oxaliplatin by regulating the Hippo-YAP pathway.

Biochim Biophys Acta Mol Basis Dis

January 2025

Department of Radiation Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou City, Guangdong Province 510280, China. Electronic address:

Background: Oxaliplatin is the first-line chemotherapy for patients with colon cancer (CC). However, its resistance limits its therapeutic efficacy.

Methods: Oxaliplatin resistance-associated differentially expressed genes (DEGs) in the GSE42387 and GSE227315 datasets were identified through bioinformatics methods.

View Article and Find Full Text PDF

Polysaccharides from maggot extracts suppress colorectal cancer progression by inducing ferroptosis via HMOX1/GPX4 signaling pathway.

Int J Biol Macromol

January 2025

the Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing 210009, China; Jiangsu Key Laboratory of Molecular and Translational Cancer Research, 42 Baiziting Road, Xuanwu District, Nanjing 210009, China. Electronic address:

Maggots contain various kinds of polysaccharides and recent studies mostly concentrated on their anti-inflammatory functions. While the molecule mechanisms related to the polysaccharides inhibiting carcinogenesis remains unclear. Here we characterized the polysaccharides extracted from maggot (MEs) determining their anti-colon cancer potentials.

View Article and Find Full Text PDF

Colon cancer is a leading cause of cancer-related morbidity and mortality worldwide, necessitating advancements in therapeutic strategies to improve outcomes. Current treatment modalities, including surgery, chemotherapy, and radiation, are limited by systemic toxicity, low drug utilization rates, and off-target effects. Colon-targeted drug delivery systems (CDDS) offer a promising alternative by leveraging the colon's unique physiology, such as near-neutral pH and extended transit time, to achieve localized and controlled drug release.

View Article and Find Full Text PDF

Background And Purpose: Cancer is one of the most prevalent diseases in the general population, and is one of the main causes of changes in the population's illness profile. In this study, we assessed changes in the functional status and quality of life of patients in the first months of chemotherapy treatment.

Method: A prospective cohort study was carried out, collecting data from cancer patients seen at an outpatient clinic in the Midwest of Santa Catarina who had breast, lung, colon and rectum, prostate and head and neck cancer.

View Article and Find Full Text PDF

'Pseudokidney' And 'Donut' signs of Colon cancer on Point-of-Care Ultrasound.

QJM

January 2025

Gastroenterology Unit, Department of Medicine, RIPAS Hospital, Jalan Putera Al-Muhtadee Billah, Bandar Seri Begawan, BA1712, Brunei Darussalam.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!